MRNA vs ONC
Moderna and BeOne Medicines AG, both Healthcare
BeOne Medicines AG is the larger company at $28B against $25B. Over the past year MRNA returned +93% against +26% for ONC. Ryufin's sector-relative Smart Score puts MRNA ahead, 9/10 against 8/10.
| Figure | MRNA | ONC |
|---|---|---|
| Last close | $62.96 | $376 |
| Market cap | $25B | $28B |
| 1-year return | +93% | +26% |
| 5-year return | -81% | +15% |
| Ryufin Smart Scoresector-relative, 1–10 | 9/10 | 8/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Moderna
Revenue of $145M in Q2 2026, net income null. Its largest reported line is COVID19, 81% of the disclosed total.
BeOne Medicines AG
Open these two in the interactive comparison to add more names, change the period or read the correlation.